Leucinostatins from Ophiocordyceps spp. and Purpureocillium spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer.

Journal of Natural Products
Yun-Seo KilRobert H Cichewicz

Abstract

The structures of four leucinostatin analogues (1-4) from Ophiocordyceps spp. and Purpureocillium spp. were determined together with six known leucinostatins [leucinostatins B (5), A (6), B2 (7), A2 (8), F (9), and D (10)]. The structures of the metabolites were established using a combination of analytical methods including HRESIMS and MS/MS experiments, 1D and 2D NMR spectroscopy, chiral HPLC, and advanced Marfey's analysis of the acid hydrolysate, as well as additional empirical and chemical methods. Compounds 1-10 were evaluated for their biological effects on triple negative breast cancer (TNBC) cells. Leucinostatins 1-10 showed selective cytostatic activities in MDA-MB-453 and SUM185PE cells representing the luminal androgen receptor subtype of TNBC. This selective activity motivated further investigation into the mechanism of action of leucinostatin B (5). The results demonstrate that this peptidic fungal metabolite rapidly inhibits mTORC1 signaling in leucinostatin-sensitive TNBC cell lines, but not in leucinostatin-resistant cells. Leucinostatins have been shown to repress mitochondrial respiration through inhibition of the ATP synthase, and we demonstrated that both the mTORC1 signaling and LAR-selective activities of...Continue Reading

References

Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Mar 1, 1973·The Journal of Antibiotics·T AraiK Yazawa
Aug 1, 1983·The Journal of Antibiotics·Y MoriT Arai
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Jan 17, 2008·Current Opinion in Obstetrics & Gynecology·Soonmo Peter KangLyndsay N Harris
Jan 20, 2010·Biochemical and Biophysical Research Communications·Isao MomoseDaishiro Ikeda
Apr 21, 2010·The Journal of Organic Chemistry·Alberto PlazaCarole A Bewley
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroko MasudaNaoto T Ueno
Sep 4, 2014·The Journal of Antibiotics·Ana Flávia Canovas Martinez, Luiz Alberto Beraldo Moraes
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Oct 11, 2014·Journal of Natural Products·Bin WangRobert H Cichewicz
Feb 9, 2016·Journal of Natural Products·David J Newman, Gordon M Cragg
Jun 4, 2016·Breast Cancer Research and Treatment·Andrew J RoblesSusan L Mooberry
Apr 14, 2018·Acta Crystallographica. Section D, Structural Biology·Renate GessmannKyriacos Petratos
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 19, 2019·Science Translational Medicine·Gloria V EcheverriaHelen Piwnica-Worms
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 13, 2020·Journal of Natural Products·David J Newman, Gordon M Cragg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.